GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...
Mississauga: GSK has announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or ...
Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in adults with moderate-to-severe anaemia. The once-daily, oral treatment is ...
Zacks.com on MSN1h
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria StudyIncyte INCY suffered a setback in its ongoing mid-stage study on MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).
Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...
Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime restrictions indicated for adult patients ...
Now given the trade name Ojjaara, GSK's once-daily oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor can be given as an alternative to other JAK inhibitors in the first-line setting ...
saw new competition arrive on the market last month with the FDA's approval of GSK’s Ojjaara (momelotinib). Jakafi accounted for $682 million of Incyte’s second-quarter sales of $827 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback